Skip to main content
main-content

Type 2 diabetes

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews editor's pick

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Heartbeat

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

medwireNews editor's pick

Adding second diabetes medication better than switching in face of poor response

Addition

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

medwireNews editor's pick

Behavioral intervention has durable physical activity effect in type 2 diabetes

Exercise

A behavioral intervention has lasting effects on physical activity levels, fitness, and vascular risk in people with type 2 diabetes, show the 3-year results of the randomized Italian Diabetes and Exercise Study 2.

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity [read more].

Get more on: Mental health and diabetesDiabetes complications and comorbidities | Diabetes in older adults

medwireNews editor's pick

d-Nav system helps people with type 2 diabetes optimize insulin doses

Compass

The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.

Patient case study

Cardiovascular risk reduction in type 2 diabetes

Heart and stethoscope

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this case study [read more].

Get more on: Cardiovascular disease | SGLT2 inhibitors | GLP-1 receptor agonists

medwireNews editor's pick

Gap in cardiovascular risk not closing for people with type 2 diabetes

Heartbeat

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

medwireNews editor's pick

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

Pills_yellow

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

medwireNews editor's pick

High mental illness burden in young-onset type 2 diabetes

Hospital

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

Interactive patient case study

Hypoglycemia and technology

Hypoglycemia and technology

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

Get more on: Hypoglycemia | Devices and technology | Pediatric diabetes

medwireNews editor's pick

No fracture risk found with canagliflozin in real-world data

Cervical hip (femoral neck) fracture

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

medwireNews editor's pick

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin pens

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

Expert opinion editorial

Diabetes and obstructive sleep apnea syndrome: Double trouble

Sleep apnea (symbolic image with model)

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition [read more].

Get more on: Sleep disorders | Obesity | Type 2 diabetes complications

medwireNews editor's pick

Possible bile duct cancer risk with incretin-based medications

Mixed pills

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

medwireNews editor's pick

Older type 2 diabetes patients may derive greatest liraglutide benefits

Elderly diabetic patient (symbolic image with models)

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

medwireNews editor's pick

Shift work plus unhealthy lifestyle add up to high diabetes risk

Clock

The total diabetes risk associated with the combination of rotating shift work and an unhealthy lifestyle is greater than that of the two added together, shows an analysis of the Nurses’ Health Studies.

medwireNews editor's pick

Research predicts ‘highly inadequate’ insulin access in coming years

Insulin pens

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

03-04-2019 | Mental health | Editorial | Article

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

02-28-2019 | Insulin | Commentary | Article

The DUNE study: Insulin and inertia in real-world practice

Jay Shubrook comments on the findings of the multinational DUNE study of glycemic target achievement in people with type 2 diabetes taking insulin.

01-30-2019 | Cardiovascular outcomes | Case study | Article

Cardiovascular risk reduction in type 2 diabetes

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

Downloadable slides

10-31-2018 | Slideset | Collection

FreeStyle Libre collection

These slide sets summarize the results of randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.

Funded by an educational grant from Abbott Diabetes Care

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits